Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

LILLY TAPS DANIELS AS PRESIDENT NORTH AMERICAN PHARMACEUTICAL OPERATIONS following the departure of Ronald Matricaria, who has joined the St. Paul-based mechanical heart valve firm St. Jude Medical as president and CEO. The promotion of Mitchell Daniels, announced by Lilly on March 17, moves a young exec with a background rooted in Republican politics and corporate affairs into the top slot in Lilly's U.S. pharmaceutical business. Commenting on areas of responsibility Daniels will see in his new post, Lilly Exec VP and Pharmaceutical Division President Sidney Taurel noted that Daniels has been "actively involved in our corporate pharmaceutical business planning." In particular, Taurel pointed out, Daniels "will bring his experience to bear on the changes that anticipated health care reform will make in our North American operations." Daniels reports to Taurel, 43. Both Daniels and Taurel are part of the team assembled by Lilly President and CEO Vaughn Bryson, 54, who took the topsider slot at Lilly in September 1991. Daniels, 43, joined Lilly in August 1990 as VP-corporate affairs from the Hudson Institute, a conservative Indianapolis think-tank where he was president and CEO. From 1971-82, he worked for Indianapolis mayor and then Indiana Republican Sen. Lugar in various jobs, including press secretary, campaign manager and chief of staff. Daniels was the National Republican Senatorial Committee executive director in 1983-84. From February 1985-March 1987, Daniels served as President Reagan's chief political advisor and liaison to state and local officials and then left to take the top post at the Hudson Institute. While he was at the Institute, he was also "of counsel" at the Indianapolis law firm of Baker & Daniels. Reagan named Daniels to the Advisory Commission on Intergovernmental Relations and later to director of the Overseas Private Investment Corp. During the 1992 presidential election campaign, Daniels volunteered some of his time on behalf of President Bush. Daniels received his undergraduate degree in 1971 from Princeton University's Woodrow Wilson School of Public and International Affairs and his JD degree in 1979 from Georgetown. Matricaria, whom Daniels succeeds, was named president of the North American pharmaceutical operations in October 1992 as part of a restructuring to create a unified worldwide organization when Taurel was announced as the new president of the pharmaceutical division and corporate exec VP ("The Pink Sheet" Oct. 5, 1992, T&G-8). Matricaria previously was president of Lilly's medical devices and diagnostics division. Succeeding Daniels as VP-corporate affairs is Stephen Stitle, 47. Stitle, a 22-year Lilly veteran, was previously VP-human resources. Pedro Granadillo, the current VP-pharmaceutical manufacturing, succeeds Stitle at human resources. Like Daniels, Stitle has a background that includes government relations. He has been director of governmental relations in Washington, D.C. (1977-80); president and manager of Lilly Canada (1981-83); the corporate secretary and deputy general counsel (1983-84); and president of the former Monoclonal Products Division at Lilly (1986-1988). Stitle was named to the human resources post in January 1988. He became a member of Lilly's board in 1991. Stitle received his BA from Indiana University (1967) and his law degree from the university in 1970. Granadillo, an engineer by training, joined Lilly in 1970. He was named VP-pharmaceutical manufacturing in June 1992 and had been executive director of production operations and manufacturing strategy development since December 1989.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts